Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
Want to see NAUT full AI Analyst Report?
NAUT Stock Chart & Stats
$3.03
$0.07(3.48%)
At close: 4:00 PM EST
$3.03
$0.07(3.48%)
Day’s Range― - ―
52-Week Range$0.62 - $4.31
Previous CloseN/A
Volume21.91K
Average Volume (3M)394.63K
Market Cap
$287.20M
Enterprise Value$362.44M
Total Cash (Recent Filing)$95.87M
Total Debt (Recent Filing)$28.87M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 04, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding127,078,860
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-118.29
Enterprise Value/Ebitda-6.45
Forecast
1Y Price Target
$4.00Price Target Upside32.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
Differentiated Proteoform CapabilityNautilus's single-molecule proteoform data produced novel Tau–ApoE biology with collaborators, demonstrating a differentiated scientific capability. Durable differentiation can drive publications, partner adoption, and proprietary datasets that support long-term demand and platform defensibility.
Verified Service Lab And Assay ProgressCompleted verification/validation for a Tau proteoform assay and standardized data packages reduce technical and operational risk. Proven lab processes and reproducible outputs are sustainable prerequisites for scaling services, customer trust, and repeatable revenue as commercial deployments progress.
Cash Position And Cost DisciplineA material cash balance combined with year-over-year expense reductions gives the company time to complete commercialization milestones. This financial cushion supports continued R&D, verification work, and measured commercial hires, lowering near-term financing and execution pressure.
Bears Say
Pre-commercial Financial LossesThe company remains pre-commercial with zero trailing revenue and large, persistent negative free cash flow. Over months this necessitates external funding or significant margin improvement; ongoing losses have eroded equity and sustain dilution and execution risk until meaningful revenue arrives.
Nascent Commercial PipelineCommercialization rests on an early pipeline with a single named customer and a very small sales organization. That concentration and limited commercial capacity make revenue less predictable and slow the adoption curve, increasing reliance on successful pilot-to-scale conversions.
Technical & Timing Risk To Broadscale LaunchManagement cites remaining verification and validation before broadscale customer deployments, plus reagent timing delays. Such technical milestones materially affect launch timing; delays extend cash burn, defer recurring revenue, and amplify execution risk over the coming quarters.
Nautilus Biotechnolgy News
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.62 and its highest was $4.31 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $287.20M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Aug 04, 2026 which is in 53 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Apr 28, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.145 by $0.025.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.14.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 127,078,860 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.145. Following the earnings report the stock price went up 0.778%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nautilus Biotechnolgy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (32.01% Upside)
$4.00 (32.01% Upside)
Insider Transactions
Sold Shares
Worth $11.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 21.7%
Last 30 Days ▲ 21.7%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.20%
12-Months-Change
Fundamentals
Return on Equity
-35.04%
Trailing 12-Months
Asset Growth
-21.92%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology, Inc. is an emerging life sciences firm dedicated to pioneering a platform technology aimed at quantifying and comprehensively understanding the intricate complexities of the proteome. Their flagship offering, the Nautilus Platform, is an integrated proteomics system. It provides a complete, end-to-end solution, including specialized instruments, essential consumables, and advanced software for data analysis. Based in Seattle, Washington, the company was established in 2016.
NAUT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantive technical and commercial progress: verified service lab, strong scientific collaborator results (including novel ApoE–Tau proteoform findings), nearly tripled qualified probes, targeted oncology assay progress, and deliberate commercial hires. Financially the company reduced operating expenses YoY and exited the quarter with $143.4M in cash and a stated runway through 2027. Offsetting these positives are external delays (Middle East conflict) that pushed grant revenue recognition and some reagent development later in the year, a nascent sales pipeline with only one named EAP customer so far, remaining verification/validation work before broadscale customer deployments, and modest expected revenue (~$0.5M) for 2026. On balance, accomplishments materially outweigh the challenges but execution and timing risks remain.View all NAUT earnings summariesNAUT Stock 12 Month Forecast
Average Price Target
$4.00
▲(32.01% Upside)
Technical Analysis
Ownership Overview
45.26% Insiders
2.78% Mutual Funds
34.95% Other Institutional Investors
14.90% Public Companies and
Individual Investors